CXCL12 and breast carcinoma: When LASP1 was stably knocked down in MDA-MB-231 (MDA-MB-231: ATCC® HTB-26TM, Manassas, VA, USA) breast cancer cells, there was an ablation of CXCL12-dependent invasion through Matrigel® (Matrigel: Discovery Labware, Inc., Bedford, MA, USA) [11].